Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

46.320
+0.2600.56%
Volume:2.07M
Turnover:95.63M
Market Cap:307.43B
PE:33.65
High:46.500
Open:46.380
Low:45.920
Close:46.060
52wk High:94.869
52wk Low:45.660
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.26
T/O Rate:0.80%
Dividend:0.23
Dividend Rate:0.50%
EPS(LYR):1.376
ROE:12.46%
ROA:7.02%
PB:4.09
PE(LYR):33.65
PS:8.41

Loading ...

Hengrui Pharma's Novel Drug Application for Rezvilutamide Accepted by European Regulator

Stock News
·
Jun 22

AH Premium and Deviation Data for June 22

Stock News
·
Jun 22

Movement Alert|Hengrui Medicine Falls 3.02% in Regular Trading, Broad Pharma Sector Sell-Off Amid Geopolitical Headwinds

Market Focus
·
Jun 22

AH Share Premium and Deviation Rankings as of June 18th

Stock News
·
Jun 18

Movement Alert|Hengrui Medicine Rises 3.02% in Regular Trading, Multiple Drug Approvals and Institutional Buying Boost Sentiment

Market Focus
·
Jun 18

Schroders Increases Stake in Hengrui Pharma by 948,800 Shares at HK$54.54 Per Share

Stock News
·
Jun 17

Hengrui Pharma repurchases 120,000 A shares for ESOP; treasury stock rises to 8.31 million

Bulletin Express
·
Jun 17

Hengrui Pharma Executes Share Buyback on June 17

Stock News
·
Jun 17

China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug

MT Newswires Live
·
Jun 17

Jiangsu Hengrui Pharmaceuticals - Received Notice From Nmpa New Indication for Dalpiciclib Isethionate Tablets, Cdk4/6 Inhibitor Approved

THOMSON REUTERS
·
Jun 16

HENGRUI PHARMA Receives Clinical Trial Approval for SHR-6914 Injection

Stock News
·
Jun 16

AH Share Premium and Deviation Rankings for June 16 Closing

Stock News
·
Jun 16

Closing Data for June 15th: AH Premium and Deviation Rankings

Stock News
·
Jun 15

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Movement Alert|Hengrui Medicine Rises 3.43% in Regular Trading, Pipeline Momentum Sustained by EULAR Data and Ongoing Buybacks

Market Focus
·
Jun 12

Hengrui's Dual-Target Fusion Protein SHR-2173 Shows Promising Phase I Results for Lupus at EULAR 2026

Deep News
·
Jun 11

Hengrui Pharma repurchases 150,000 A-shares for ESOP at RMB 46.89 average

Bulletin Express
·
Jun 11

AH Share Premium and Deviation Rankings for June 11th

Stock News
·
Jun 11

Movement Alert|Hengrui Medicine Falls 3.06% in Regular Trading, Valuation Compression and Institutional Selling Continue to Weigh

Market Focus
·
Jun 11

Hengrui Pharma Repurchases 10,000 A Shares for ESOP, Outstanding Float Falls 0.0002%

Bulletin Express
·
Jun 10